Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
$1.00
+2.1%
$0.98
$0.61
$7.45
$15.08M-0.151.13 million shs294,547 shs
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
$2.90
-0.7%
$4.23
$2.75
$135.54
$2.32M-0.27461,425 shs131,052 shs
Mannatech, Incorporated stock logo
MTEX
Mannatech
$9.00
-4.8%
$10.02
$6.75
$16.49
$17.10M0.925,209 shs55,667 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.22
-6.9%
$3.23
$2.57
$20.48
$19.90M0.639,097 shs25,168 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
0.00%+7.52%+18.33%+6.37%-84.34%
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
0.00%-4.61%-28.04%-66.02%-91.83%
Mannatech, Incorporated stock logo
MTEX
Mannatech
0.00%-8.16%-8.71%-1.96%+32.55%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00%-2.72%-4.02%-6.40%-46.51%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
0.7971 of 5 stars
0.04.00.00.01.40.01.3
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
3.4191 of 5 stars
3.54.00.00.04.42.50.0
Mannatech, Incorporated stock logo
MTEX
Mannatech
0.603 of 5 stars
0.03.00.00.02.41.70.0
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.8519 of 5 stars
0.03.00.00.02.21.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
0.00
N/AN/AN/A
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
3.00
Buy$180.006,106.90% Upside
Mannatech, Incorporated stock logo
MTEX
Mannatech
0.00
N/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/AN/AN/AN/A$1.62 per shareN/A
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
N/AN/AN/AN/A($31.66) per shareN/A
Mannatech, Incorporated stock logo
MTEX
Mannatech
$117.87M0.15$2.13 per share4.22$4.57 per share1.97
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.17N/AN/A$13.32 per share0.24
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
-$24.51MN/A0.00N/AN/AN/A-147.94%-90.33%8/4/2025 (Estimated)
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
-$9.95MN/A0.00N/AN/AN/A-497.73%-147.21%7/29/2025 (Estimated)
Mannatech, Incorporated stock logo
MTEX
Mannatech
$2.49M-$0.10N/AN/A-0.19%-2.56%-0.57%8/12/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%N/A

Latest ALZN, MTEX, ALLR, and NAII Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
5/13/2025Q1 2025
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
-$8.10-$0.25+$7.85-$0.25N/AN/A
5/13/2025Q1 2025
Mannatech, Incorporated stock logo
MTEX
Mannatech
N/A-$0.80N/A-$0.80N/A$26.56 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/AN/AN/AN/AN/A
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
N/AN/AN/AN/AN/A
Mannatech, Incorporated stock logo
MTEX
Mannatech
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/A
2.66
2.66
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
N/A
5.44
5.44
Mannatech, Incorporated stock logo
MTEX
Mannatech
0.46
1.18
0.65
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35

Institutional Ownership

CompanyInstitutional Ownership
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
11.53%
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
49.61%
Mannatech, Incorporated stock logo
MTEX
Mannatech
12.98%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%

Insider Ownership

CompanyInsider Ownership
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
0.01%
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
30.21%
Mannatech, Incorporated stock logo
MTEX
Mannatech
41.50%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
20.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
1015.08 million15.08 millionNot Optionable
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
4800,000559,000No Data
Mannatech, Incorporated stock logo
MTEX
Mannatech
2501.90 million1.11 millionNot Optionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable

Recent News About These Companies

Natural Alternatives International, Inc. Announces 2025 Q2 and YTD Results
CarnoSyn Brands announces new U.S. distribution pact with B&D Nutritional
(NAII) Trading Advice
In Asia, alternative proteins are the new clean energy

New MarketBeat Followers Over Time

Media Sentiment Over Time

Allarity Therapeutics stock logo

Allarity Therapeutics NASDAQ:ALLR

$1.00 +0.02 (+2.12%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$1.01 +0.02 (+1.51%)
As of 04:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Alzamend Neuro stock logo

Alzamend Neuro NASDAQ:ALZN

$2.90 -0.02 (-0.68%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$2.96 +0.06 (+1.90%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Mannatech stock logo

Mannatech NASDAQ:MTEX

$9.00 -0.45 (-4.76%)
Closing price 06/27/2025 03:54 PM Eastern
Extended Trading
$9.39 +0.39 (+4.33%)
As of 06/27/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.22 -0.24 (-6.94%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$20.48 +17.26 (+536.02%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.